Press Release
Replimune Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference
Details of Replimune’s poster presentations:
- Title: (647) Initial results of a phase 1 trial of
RP2 , a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors:
Abstract Authors: Mark Middleton1, Joseph J. Sacco2, Kevin Harrington4,Anna Olsson -Brown2, Pablo Nenclares4, Francesca Aroldi1, Suzanne Thomas3,Robert S. Coffin , etc.
Presentation times:Wednesday, Nov. 11 from 5:15–5:45 p.m. EST andFriday, Nov. 13 from 4:40–5:10 p.m. EST
Location: Virtual Poster Hall
The poster is also available on theReplimune website linked here.
- Title: (650) An Open-label, multicenter, Phase 1/2 clinical trial of
RP1 , an enhanced potency oncolytic HSV, combined with nivolumab: Updated results from the skin cancer cohorts
Abstract Authors:Mark R. Middleton ,Francesca Aroldi ,Joseph J. Sacco ,Mohammed M. Milhem ,Brendan D. Curti ,Ari M. Vanderwalde ,Scott Baum ,Adel Samson ,Anna C. Pavlick ,Jason Alan Chesney ,Jiaxin Niu ,Terence Duane Rhodes ,Tawnya Lynn Bowles ,Robert Conry , AnnaOlsson-Brown,Douglas Earl Laux ,Praveen Bommareddy ,Alex Deterding ,Robert S. Coffin ,Kevin Harrington
Presentation times:Thursday, Nov. 12 from 4:50–5:20 p.m. EST andSaturday, Nov. 14 from 1–1:30 p.m. EST
Location: Virtual Poster Hall
The poster is also available on theReplimune website linked here. Supporting slides with patient examples are linked here.
About
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about our cash runway, the advancement of our clinical trials, our plans to initiate new clinical trials, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, the potential impact of COVID-19 on our operations and milestones, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the
Investor Inquiries
Westwicke, an
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
917.548.1582
agoldenberg@vergescientific.com
Source: Replimune Group Inc